Source - RNS
RNS Number : 2209L
Vernalis PLC
29 September 2016
 

BLOCK LISTING SIX MONTHLY RETURN

 

VERNALIS PLC (the "Company")

 

29 September 2016

 

Vernalis plc (LSE: VER) provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements:

 

Name of applicant:

Vernalis plc

Name of scheme(s):

2007 Long Term Incentive Scheme ("LTIP") and the Savings Related Share Option Plan 2003 ("SAYE")

Period of return (from / to):

From: 29/Mar/2016

To: 29/Sept/2016

Balance of unallotted securities under scheme(s) from previous return:

Total of 2,243,318 Ordinary 1p Shares, split:

· Under LTIP   =   2,243,318 Ordinary 1p Shares

· Under SAYE =   NIL Ordinary 1p Shares

Plus: The amount by which the block scheme(s) has been increased or application has been made to increase since the date of the last return (if any increase has been applied for):

NIL

Less: Number of securities issued/allotted under scheme(s) during period:

Total of 1,074,958 Ordinary 1p Shares, split:

· Under LTIP   =   1,074,958 Ordinary 1p Shares

· Under SAYE =   NIL Ordinary 1p Shares

Less: Number of securities forfeited under scheme(s) during period:

767,304

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

Total of 401,056 Ordinary 1p Shares, split:

· Under LTIP   =   401,056 Ordinary 1p Shares

· Under SAYE =   NIL Ordinary 1p Shares

Number and class of securities originally admitted and the date of admission (including any additions):

No. of Ordinary 1p Shares

Date on which Shares were Admitted to Trading

350,000

6 November 2013, plus

1,049,317

12 May 2014, plus

1,058,184

12 May 2015, plus

1,638,364

30 September 2015

1,189,296

1 April 2016

 

 

-- ends -

 

 

Enquiries:

 

Vernalis plc:

+44 (0) 118 938 0015

Ian Garland, Chief Executive Officer

 

David Mackney, Chief Financial Officer

 

 

Canaccord Genuity Limited (Nominated Adviser):

+44 (0) 20 7523 8000

Dr Julian Feneley

 

Henry Fitzgerald-O'Connor

 

Rupert Winckler

 

Emma Gabriel

 

 

Shore Capital (Joint Broker):

+44 (0) 20 7408 4090

Bidhi Bhoma

 

Toby Gibbs

 

 

FTI Consulting:

+44 (0) 20 3727 1000

Ben Atwell

 

Simon Conway

 

Stephanie Cuthbert

 

 

 

Notes to Editors

 

About Vernalis

Vernalis is a revenue generating, commercial stage pharmaceutical company with significant expertise in drug development.  The Group has three approved products: Tuzistra®XR targeting the US prescription cough cold market; MOXATAG®, a once-a-day formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes and frovatriptan for the acute treatment of migraine. It has an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as eight programmes in its NCE development pipeline.  Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies.  The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier Taisho and Tris.

 

For further information about Vernalis, please visit www.vernalis.com 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRLLMMTMBATBBF

Related Charts

Vernalis (VER)

+0.63p (+1.86%)
delayed 18:15PM